Fresenius Medical Care AG (FMS)
| Market Cap | 11.52B -27.7% |
| Revenue (ttm) | 22.19B -0.5% |
| Net Income | 1.07B +42.9% |
| EPS | 1.88 +50.0% |
| Shares Out | 266.11M |
| PE Ratio | 11.48 |
| Forward PE | 9.81 |
| Dividend | $0.61 (2.81%) |
| Ex-Dividend Date | May 22, 2026 |
| Volume | 329,689 |
| Open | 21.53 |
| Previous Close | 21.41 |
| Day's Range | 21.45 - 21.67 |
| 52-Week Range | 20.02 - 27.43 |
| Beta | 0.81 |
| Analysts | Hold |
| Price Target | 23.92 (+10.95%) |
| Earnings Date | Nov 3, 2026 |
About FMS
Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, the United States, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient’s residence; and dialysis services under contract to hospitals in the United States for the hospital... [Read more]
Financial Performance
In 2025, Fresenius Medical Care AG's revenue was 19.63 billion, an increase of 1.51% compared to the previous year's 19.34 billion. Earnings were 978.37 million, an increase of 81.88%.
Financial numbers in EUR Financial StatementsAnalyst Summary
According to 7 analysts, the average rating for FMS stock is "Hold." The 12-month stock price target is $23.92, which is an increase of 10.95% from the latest price.
News
Fresenius Medical Care Brings Kidney Care Innovation to Critical Care Patients with U.S. Launch of multiFiltratePRO™
Expands access to Fresenius Medical Care's globally established portfolio of advanced kidney replacement therapies in the U.S. FDA clearance of multiFiltratePRO and approval of dedicated solutions exp...
Investors unlikely to find positive Fresenius take from HHS plan, says JPMorgan
After HHS published a new Kidney Care National Plan, JPMorgan said bears will focus on the strong rhetoric around the large incumbent providers, Fresenius Medical (FMS) and DaVita (DVA), and…
EQS-DD: Fresenius Medical Care AG: Martin Fischer, Acquisition of shares under the Fresenius Medical Care Management Board Long Term Incentive Plan 2020 (Allocation 2023)
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them 19.10.2026 / 17:16 CET/CEST The issuer is solely responsi...
Fresenius Medical Care presents new evidence and innovations advancing kidney care at ASN Kidney Week 2026
BAD HOMBURG, Germany, Oct. 19, 2026 /PRNewswire/ -- Fresenius Medical Care (FME), the world's leading provider of products and services for people with kidney disease, presents new research and eviden...
Fresenius Medical price target lowered to $24 from $25 at Truist
Truist lowered the firm’s price target on Fresenius Medical (FMS) to $24 from $25 and keeps a Hold rating on the shares as part of broader research now previewing Q3…
Fresenius Medical Care Names Shervin Korangy CEO
(RTTNews) - Fresenius Medical Care AG (FME.DE, FME) announced that Shervin J. Korangy will become Chief Executive Officer (CEO) and Chair of the Management Board, effective October 12, 2026. He will s...
Fresenius Medical Care AG (FMS) Shares Fall 7.7% -- What GF Score of 74 Tells Investors
Fresenius Medical Care AG (FMS) Shares Fall 7.7% -- What GF Score of 74 Tells Investors
Fresenius Medical Care (FMS) Names Shervin Korangy as New CEO and Chair
Fresenius Medical Care (FMS) Names Shervin Korangy as New CEO and Chair
Fresenius Medical trading resumes
11:10 EDT Fresenius Medical (FMS) trading resumes
Fresenius Medical names Shervin Korangy as next CEO
Fresenius Medical (FMS) announced that Shervin Korangy will become Chief Executive Officer and Chair of the Management Board, effective October 12. The supervisory board unanimously appointed Korangy ...
EQS-Adhoc: Fresenius Medical Care AG : Change in CEO – Shervin J. Korangy Succeeds Helen Giza
EQS-Ad-hoc: Fresenius Medical Care AG / Key word(s): Personnel decisions / Executive Board Fresenius Medical Care AG : Change in CEO – Shervin J. Korangy Succeeds Helen Giza 07-Oct-2026 / 16:54 CET/CE...
Fresenius Medical trading halted, news pending
10:37 EDT Fresenius Medical (FMS) trading halted, news pending
Fresenius Medical downgraded to Hold from Buy at Berenberg
Berenberg downgraded Fresenius Medical (FMS) to Hold from Buy with a price target of EUR 42, down from EUR 60, following a transfer of coverage. Evidence of positive U.S. kidney…
Fresenius Medical Care Refines China Commercial Strategy with a Focus on Long-Term Growth and Market Leadership
Refinements support the Company's China go-to-market and commercial strategy in an important and growing market Strategy focuses on localized portfolio and innovation in China Portfolio decisions expe...
Fresenius Medical Care AG (FMS) Stock Down 3.9% -- Now Undervalued? GF Score: 74/100
Fresenius Medical Care AG (FMS) Stock Down 3.9% -- Now Undervalued? GF Score: 74/100
EQS-PVR: Fresenius Medical Care AG: Publication of acquisition or disposal in respect of own shares according Sec. 40 para. 1 sent. 2 WpHG
EQS Voting Rights Announcement: Fresenius Medical Care AG Fresenius Medical Care AG: Publication of acquisition or disposal in respect of own shares according Sec. 40 para. 1 sent. 2 WpHG 10.09.2026 /...
Fresenius Medical Care Becomes Oversold (FMS)
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a tec...
Can Fresenius Medical's 5008X Rollout Drive the Next Growth Phase?
Fresenius Medical is scaling its 5008X rollout across U.S. clinics, creating growth potential despite volume, reimbursement and rollout-cost pressures.
EQS-PVR: Fresenius Medical Care AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
EQS Voting Rights Announcement: Fresenius Medical Care AG Fresenius Medical Care AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Eu...
Fresenius Cuts Fresenius Medical Care Stake, Raises About €300 Mln
(RTTNews) - Fresenius SE & Co. KGaA (FRE.DE) announced that it has agreed to sell approximately 7.8 million shares in Fresenius Medical Care AG (FMS), representing about 2.9% of the dialysis company's...
3 Cheap International Stocks to Buy
These stocks have economic moats and look attractive today.
EQS-CMS: Fresenius Medical Care AG : Release of a capital market information
EQS Post-admission Duties announcement: Fresenius Medical Care AG / Disclosure pursuant to Art. 5 para. 1 lit. b) of Regulation (EU) No. 596/2014 Fresenius Medical Care AG : Release of a capital marke...
Fresenius Medical Care (FMS) Q2 2026 Earnings Call Transcript
U.S. referral execution gap offset by strong margin expansion and transformation savings.
Fresenius Medical price target raised to $25.80 from $25.50 at Bernstein
Bernstein analyst Susannah Ludwig raised the firm’s price target on Fresenius Medical (FMS) to $25.80 from $25.50 and keeps a Market Perform rating on the shares. The firm notes the…
Fresenius Medical price target lowered to EUR 32.30 from EUR 37.40 at JPMorgan
JPMorgan analyst David Adlington lowered the firm’s price target on Fresenius Medical (FMS) to EUR 32.30 from EUR 37.40 and keeps an Overweight rating on the shares. Published first on…